Plexiform Neurofibroma Clinical Trials 2023

What are the top hospitals conducting plexiform neurofibroma research?

When it comes to groundbreaking clinical trials in the realm of plexiform neurofibroma, several hospitals are leading the way. At the National Institutes of Health Clinical Center, located in Bethesda, researchers are actively conducting four trials focused on this condition and have accumulated a total of nine studies since their first recorded trial in 2008. Not far away at Children's National Medical Center in Washington D.C., three active trials are currently underway, building upon seven previous investigations conducted since their initial foray into plexiform neurofibroma research back in 2002.

The National Institutes of Health Clinical Center expands its influence with another location on Rockville Pike still within Bethesda where an additional three active clinical trials for plexiform neurofibroma can be found alongside a remarkable track record encompassing eleven completed studies since they embarked on their inaugural trial back in 2001.

Cincinnati Children's Hospital Medical Center is also making significant contributions to the field. With two ongoing clinical trials focusing on plexiform neurofibroma and a cumulative history comprising five past studies starting from their pioneer investigation dated 2008.

Adding itself recently to this esteemed list is Nationwide Children's Hospital located in Columbus which has initiated two current clinical researches delving into plexiform neurofibroma; these significant steps represent vital milestones for them as they delve themselves only deeper into uncharted territory while having executed previously just about average-level experiments,two being exact so far that was started solely from2017.

These top-ranking hospitals serve as beacons of hope and progress when it comes to understanding and treating plexiform neurofibromas—a condition characterized by tumors along nerve fibers that can cause pain, deformities, or other complications. Their relentless pursuit of knowledge through rigorous clinical trials brings us closer than ever before to innovative treatments and improved outcomes for patients affected by this challenging disorder—a testament to medical advancement happening right now!

Which are the best cities for plexiform neurofibroma clinical trials?

When it comes to plexiform neurofibroma clinical trials, several cities stand out as hubs for research and development. Bethesda, Maryland leads the pack with 8 active trials focused on investigating treatments like Selumetinib, Turalio, and AZD6244. Los Angeles, California; Washington, District of Columbia; Chicago, Illinois; and Cincinnati, Ohio all have 4 active trials each that explore options such as Mirdametinib (PD-0325901) oral capsule or dispersible tablet and Binimetinib. These cities offer individuals with plexiform neurofibroma access to ongoing studies that can potentially lead to breakthroughs in treatment options and improved outcomes.

Which are the top treatments for plexiform neurofibroma being explored in clinical trials?

The field of plexiform neurofibroma research is witnessing significant advancements in clinical trials. Selumetinib, with three active trials and six all-time plexiform neurofibroma trials since its introduction in 2016, stands out as a top treatment option. Another promising contender is Mirdametinib (PD-0325901) oral capsule or dispersible tablet, currently being explored in one active trial and one all-time plexiform neurofibroma trial after its listing in 2019. Additionally, the Medication Event Monitoring System (MEMS), Binimetinib, and Turalio are also undergoing investigation for potential effectiveness against this condition through ongoing clinical studies. Exciting possibilities lie ahead as researchers continue to explore these treatments' capabilities to combat plexiform neurofibroma.

What are the most recent clinical trials for plexiform neurofibroma?

Exciting advancements in the field of plexiform neurofibroma research are offering hope for patients. One notable clinical trial is investigating the effectiveness of selumetinib, a promising drug that has reached Phase 3 trials as of November 19, 2021. Another phase one trial with selumetinib was made available on July 21, 2021. Additionally, mirdametinib (PD-0325901) oral capsule or dispersible tablet is being evaluated in a Phase 2 study since September 6,2019. Binimetinib has also shown promise and is currently undergoing Phase two testing after becoming available on November 28th,2017 . These ongoing trials present potential breakthroughs for individuals living with plexiform neurofibromas and offer renewed optimism for improved treatment options in the future

What plexiform neurofibroma clinical trials were recently completed?

Recently completed clinical trials in the field of plexiform neurofibroma have made significant strides towards advancing treatments for this condition. These trials include a study on PLX8394 conducted by the National Cancer Institute, which concluded in October 2021. Another trial sponsored by AstraZeneca and MedImmune investigated selumetinib and was successfully completed in September 2021. Additionally, an investigational treatment known as LXH254 underwent clinical testing and reached completion in January 2021. The successful conclusion of these trials represents important progress in the development of therapies for patients with plexiform neurofibroma.